Absci Corp. (ABSI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$9.18-2.03%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Absci Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.1M
EPS	—	-0.195
Annual ending 2026-12-31
Revenue	—	3.89M
EPS	—	-0.8
Annual ending 2027-12-31
Revenue	—	15.99M
EPS	—	-0.73

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient cash to fund operations into first half of 2028	The company aims to fund operations into mid-2028.	Intact	cash runway falls short of mid-2028 funding needs	Runway into 2H 2028 vs H1 2028 target Aug 2026 news confirms cash runway guidance into 2H 2028, surpassing the mid-2028 requirement. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce negative EPS from -$0.76 in 2026 to less negative in 2027	A primary condition in Absci Corp.'s published investment case. The stated target is EPS improves from -$0.76 in FY26 to > -$0.63 in FY27.	Broken	EPS worsens beyond -$0.76 in FY26 or fails to improve in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth from $5.47M in 2026 to $16.5M in 2027	A primary condition in Absci Corp.'s published investment case. The stated target is >= $16.5M revenue in FY27.	Broken	revenue falls below $5.5M in FY26 or fails to grow toward $16.5M in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.73

$-0.70 → $-0.73 · observed estimates

FY2027 revenue$0.02B

$0.02B → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.70	$17,675,550	7 / 8
2026-07-25	$-0.70	$17,675,550	7 / 8
2026-07-26	$-0.70	$17,675,550	7 / 8
2026-07-27	$-0.70	$17,675,550	7 / 8
2026-07-28	$-0.62	$17,675,550	9 / 10
2026-07-29	$-0.62	$17,675,550	9 / 10
2026-07-30	$-0.62	$17,675,550	9 / 10
2026-07-31	$-0.62	$17,675,550	9 / 10
2026-08-01	$-0.70	$17,675,550	7 / 8
2026-08-02	$-0.62	$17,675,550	9 / 10
2026-08-03	$-0.62	$17,675,550	9 / 10
2026-08-04	$-0.62	$17,675,550	9 / 10
2026-08-05	$-0.62	$17,675,550	9 / 10
2026-08-06	$-0.62	$17,675,550	9 / 10
2026-08-07	$-0.62	$17,675,550	9 / 10
2026-08-08	$-0.62	$17,675,550	9 / 10
2026-08-09	$-0.62	$17,675,550	9 / 10
2026-08-10	$-0.62	$17,675,550	9 / 10
2026-08-11	$-0.70	$17,675,550	7 / 8
2026-08-12	$-0.62	$17,675,550	9 / 10
2026-08-13	$-0.62	$17,675,550	9 / 10
2026-08-14	$-0.70	$17,675,550	7 / 8
2026-08-15	$-0.70	$17,675,550	6 / 8
2026-08-16	$-0.70	$17,675,550	6 / 8
2026-08-17	$-0.70	$17,675,550	6 / 8
2026-08-18	$-0.70	$17,675,550	6 / 8
2026-08-19	$-0.70	$17,675,550	6 / 8
2026-08-20	$-0.70	$17,675,550	6 / 8
2026-08-21	$-0.71	$16,145,550	6 / 8
2026-08-22	$-0.71	$16,145,550	6 / 8
2026-08-23	$-0.71	$16,145,550	6 / 8
2026-08-24	$-0.71	$16,145,550	6 / 8
2026-08-25	$-0.71	$16,145,550	6 / 8
2026-08-26	$-0.71	$16,145,550	6 / 8
2026-08-27	$-0.71	$16,145,550	6 / 8
2026-08-28	$-0.71	$16,145,550	6 / 8
2026-08-29	$-0.71	$16,145,550	6 / 8
2026-08-30	$-0.71	$16,145,550	6 / 8
2026-08-31	$-0.71	$16,145,550	6 / 8
2026-09-01	$-0.71	$16,145,550	6 / 8
2026-09-02	$-0.71	$16,145,550	6 / 8
2026-09-03	$-0.71	$16,145,550	6 / 8
2026-09-04	$-0.71	$16,145,550	6 / 8
2026-09-05	$-0.71	$16,145,550	6 / 8
2026-09-06	$-0.71	$16,145,550	6 / 8
2026-09-07	$-0.71	$16,145,550	6 / 8
2026-09-08	$-0.71	$16,145,550	6 / 8
2026-09-09	$-0.71	$16,145,550	6 / 8
2026-09-10	$-0.71	$16,145,550	6 / 8
2026-09-11	$-0.71	$16,145,550	6 / 8
2026-09-12	$-0.71	$16,145,550	6 / 8
2026-09-13	$-0.71	$16,145,550	6 / 8
2026-09-14	$-0.71	$16,145,550	6 / 8
2026-09-15	$-0.71	$16,145,550	6 / 8
2026-09-16	$-0.71	$16,145,550	6 / 8
2026-09-17	$-0.71	$16,145,550	6 / 8
2026-09-18	$-0.71	$16,145,550	6 / 8
2026-09-19	$-0.71	$16,145,550	6 / 8
2026-09-20	$-0.71	$16,145,550	6 / 8
2026-09-21	$-0.71	$16,145,550	6 / 8
2026-09-22	$-0.71	$16,145,550	6 / 8
2026-09-23	$-0.71	$16,145,550	6 / 8
2026-09-24	$-0.71	$16,145,550	6 / 8
2026-09-25	$-0.71	$16,145,550	6 / 8
2026-09-26	$-0.71	$16,145,550	6 / 8
2026-09-27	$-0.71	$16,145,550	6 / 8
2026-09-28	$-0.71	$16,145,550	6 / 8
2026-09-29	$-0.71	$16,145,550	6 / 8
2026-09-30	$-0.71	$16,145,550	6 / 8
2026-10-01	$-0.72	$15,995,550	6 / 8
2026-10-02	$-0.72	$15,995,550	6 / 8
2026-10-03	$-0.72	$15,995,550	6 / 8
2026-10-04	$-0.72	$15,995,550	6 / 8
2026-10-05	$-0.72	$15,995,550	6 / 8
2026-10-06	$-0.72	$15,995,550	6 / 8
2026-10-07	$-0.72	$15,995,550	6 / 8
2026-10-08	$-0.72	$15,995,550	6 / 8
2026-10-09	$-0.72	$15,995,550	6 / 8
2026-10-10	$-0.72	$15,995,550	6 / 8
2026-10-11	$-0.72	$15,995,550	6 / 8
2026-10-12	$-0.72	$15,995,550	6 / 8
2026-10-13	$-0.72	$15,993,750	6 / 8
2026-10-14	$-0.72	$15,993,750	6 / 8
2026-10-15	$-0.72	$15,993,750	6 / 8
2026-10-16	$-0.72	$15,993,750	6 / 8
2026-10-17	$-0.72	$15,993,750	6 / 8
2026-10-18	$-0.72	$15,993,750	6 / 8
2026-10-19	$-0.72	$15,993,750	6 / 8
2026-10-20	$-0.72	$15,993,750	6 / 8
2026-10-21	$-0.72	$15,993,750	6 / 8
2026-10-22	$-0.72	$15,993,750	6 / 8
2026-10-23	$-0.73	$15,993,750	6 / 8
2026-10-24	$-0.73	$15,993,750	6 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	1
2026-06-01	10	1
2026-07-01	10	1
2026-08-01	9	1
2026-09-01	10	1
2026-10-01	10	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce negative EPS from -$0.76 in 2026 to less negative in 2027Published status: Broken
Revenue growth from $5.47M in 2026 to $16.5M in 2027Published status: Broken

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.7%Typical daily move · historical

Downside history

-48.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Absci Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth thesis, not a proven earnings compounder. The thesis is on watch: management’s clinical priorities remain on track by its account, but recent financial performance trails its industry cohort and the business remains loss-making.

What's priced into Absci Corp.

ABSI is tagged as stretched, with a large premium versus peers and low confidence in the valuation model. The expectations gap is tied to optionality, meaning investors appear to assign value to possible future outcomes despite limited current earnings support.

What the fundamentals likely do

Near term, results may remain uneven: recent earnings were in line after an earlier reported beat, and the next print carries elevated miss risk. Management says ABS-201 milestones remain on track, while cash rose after an equity offering and is expected to fund operations into the second half of 2028; the AI platform has no direct financial metrics in the evidence.

What Absci Corp. hinges on

The multi-year view depends on progress in ABS-201, including interim proof-of-concept data expected in the second half of 2026 and full data in early 2027, plus the planned Phase 2 endometriosis trial. A guidance cut would be a meaningful negative, while continued strength from healthcare bellwethers could support sector sentiment; weakening employment data could add pressure to healthcare names.